Moran, Michael
Nickens, Dana
Adcock, Katherine
Bennetts, Meg
Desscan, Arial
Charnley, Natalie
Fife, Kate
Funding for this research was provided by:
Pfizer Inc
Article History
First Online: 12 July 2019
Compliance with ethical standards
:
: This study was sponsored by Pfizer Inc.
: Michael Moran, Dana Nickens, and Meg Bennetts are employees of Pfizer Inc. Arial Desscan is currently an employee of Pfizer (undergraduate program). Katherine Adcock was an employee of Pfizer between Sept 2017 and 2018 (undergraduate program). Natalie Charnley has received honoraria for lecture fees and advisory boards from Pfizer, Ipsen, and Janssen. Kate Fife has received honoraria for advice or lecture fees from BMS, Pfizer, Esai, Novartis, and Roche.
: Upon request, and subject to certain criteria, conditions, and exceptions (see ExternalRef removed for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the US and/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.